JP2026507878A - 膵臓癌の処置のための複合薬 - Google Patents

膵臓癌の処置のための複合薬

Info

Publication number
JP2026507878A
JP2026507878A JP2025551865A JP2025551865A JP2026507878A JP 2026507878 A JP2026507878 A JP 2026507878A JP 2025551865 A JP2025551865 A JP 2025551865A JP 2025551865 A JP2025551865 A JP 2025551865A JP 2026507878 A JP2026507878 A JP 2026507878A
Authority
JP
Japan
Prior art keywords
cancer
regimen
minnelide
administered
paclitaxel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025551865A
Other languages
English (en)
Japanese (ja)
Other versions
JP2026507878A5 (enExample
Inventor
アール． ヴェラガプディ，モハナ
クマール サルジャ，アショク
Original Assignee
ミネアムリタ セラピューティクス， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミネアムリタ セラピューティクス， エルエルシー filed Critical ミネアムリタ セラピューティクス， エルエルシー
Publication of JP2026507878A publication Critical patent/JP2026507878A/ja
Publication of JP2026507878A5 publication Critical patent/JP2026507878A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2025551865A 2023-03-09 2023-03-21 膵臓癌の処置のための複合薬 Pending JP2026507878A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363489221P 2023-03-09 2023-03-09
US63/489,221 2023-03-09
PCT/US2023/015813 WO2024186320A1 (en) 2023-03-09 2023-03-21 Drug combination for treatment of pancreatic cancer

Publications (2)

Publication Number Publication Date
JP2026507878A true JP2026507878A (ja) 2026-03-06
JP2026507878A5 JP2026507878A5 (enExample) 2026-03-31

Family

ID=92675407

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025551865A Pending JP2026507878A (ja) 2023-03-09 2023-03-21 膵臓癌の処置のための複合薬

Country Status (5)

Country Link
EP (1) EP4676463A1 (enExample)
JP (1) JP2026507878A (enExample)
KR (1) KR20250154513A (enExample)
AU (1) AU2023435819A1 (enExample)
WO (1) WO2024186320A1 (enExample)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596977B (zh) 2009-05-07 2016-06-29 明尼苏达大学评议会 雷公藤内酯前药
US9150600B2 (en) 2009-05-07 2015-10-06 Regents Of The University Of Minnesota Triptolide prodrugs
US9511046B2 (en) * 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
WO2014167581A2 (en) * 2013-04-01 2014-10-16 Laurus Labs Private Limited An improved process for the preparation of triptolide prodrugs
WO2015127011A1 (en) * 2014-02-21 2015-08-27 Institute Of Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center C-myc as a biomarker for tumor sensitivity to treatment with rna polymerase ii inhibition
US10975146B2 (en) * 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
US11819498B2 (en) * 2019-12-30 2023-11-21 Unm Rainforest Innovations Methods and compositions for treating autophagy related disease states and conditions utilizing AMPK activation
WO2021231678A1 (en) * 2020-05-13 2021-11-18 University Of Massachusetts Reducing prominin2-mediated resistance to ferroptotic cell death

Also Published As

Publication number Publication date
AU2023435819A1 (en) 2025-10-02
EP4676463A1 (en) 2026-01-14
WO2024186320A1 (en) 2024-09-12
KR20250154513A (ko) 2025-10-28

Similar Documents

Publication Publication Date Title
AU2013205648B2 (en) Combination treatment
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
MX2012014231A (es) Metodos de terapia combinada para tratar enfermedades proliferativas.
JP2012515184A (ja) 大腸がんの治療方法
EP4247363A1 (en) Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
Abou-Jawde et al. Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial
WO2021155764A1 (zh) Bi853520与化疗药物的联用
TW202146007A (zh) 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
TW202038932A (zh) 使用6,8-雙-苄硫基-辛酸和自噬抑制劑治療癌症之治療方法及組成物
TW201625243A (zh) 用於治療黑素瘤之藥物組合
JP2025509278A (ja) 小細胞肺癌を治療する方法
CN107073015B (zh) 用于治疗吸烟者中的非小细胞肺癌的维利帕尼与卡铂和紫杉醇的组合
CA2912830A1 (en) Specific cancer treatment regimens with ganetespib
TW202404593A (zh) 用於治療癌症的組合療法
TW202327579A (zh) Ｔｅａｄ抑制劑的給藥方案
TW202133848A (zh) 作為bcl-2抑制劑的n-(苯基磺醯基)苯甲醯胺及相關化合物
KR20250154513A (ko) 췌장암 치료용 약물 조합
JP6708634B2 (ja) 急性骨髄性白血病及び骨髄異形成症候群の併用療法ｉｉｉ
CN110051848A (zh) 药物组合、应用以及抗肿瘤的药物
TW201244732A (en) Ezatiostat for treating multiple myeloma
US12357645B2 (en) Drug combination for treatment of gastric cancer
TW202023568A (zh) 用於治療癌症之組合療法
JP2026009993A (ja) 胃癌の治療のための薬物の組み合わせ
WO2026107242A1 (en) Ras and pd-1 or pd-l1 inhibitors combination therapy
AU2024343230A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260323